Torcetrapib’s failure raises new questions
The halt of Pfizer’s torcetrapib program has potentially far-reaching implications for the broader industry and raises questions about safety of other drugs in its class, analysts said.
The halt of Pfizer’s torcetrapib program has potentially far-reaching implications for the broader industry and raises questions about safety of other drugs in its class, analysts said.
John Wiley & Sons joins the dozen or so largest medical publishers with its acquisition of Blackwell Publishing, with scientific and medical titles comprising more than half of its business.
Schering-Plough chairman and CEO Fred Hassan has set out an agenda for the newly elected US Congress when it convenes in January.
The American Academy of Family Physicians has named ex-Ascend publisher Stephanie Hanaway to lead its titles, taking over for Joetta Melton, who is retiring.
The new Democratic leadership is poised to conduct more oversight of the Bush administration in 2007, particularly on issues involving Medicare Part D and the FDA, according to House Committee on Energy and Commerce incoming chairman John Dingell (D-MI).
Outgoing Senate Finance Committee chairman Chuck Grassley (R-IA) has written Democrat Senate HELP Committee leaders with a laundry list of FDA shortcomings that he hopes they will address in the new session beginning in January.
In November, FDA drug safety whistleblower David J. Graham and his lawyer were in pursuit of whoever posted an anti-FDA article under his name on a Canadian Web site.
Reality stared pharmaceutical marketers in the face after the mid-term elections.
Seracor’s Lunesta moth is the subject of a lawsuit from a small maker of herbal sleep aids which claims the company ripped off the butterfly logo for its Nytex treatment.
GSW Worldwide has poached two senior talents from Deutsch to head its New York creative department.